loader
Please Wait
Applying Filters...

Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about (+)-Posiphen, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Posiphen

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass

    Inke S.A: APIs manufacturing plant.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    2D Structure
    1. Also known as: (+)-phenserine, R-phenserine, 116839-68-0, (+)-posiphen, Phenserine, (+)-, Buntanetap
    Molecular Formula
    C20H23N3O2
    Molecular Weight
    337.4  g/mol
    InChI Key
    PBHFNBQPZCRWQP-AZUAARDMSA-N
    FDA UNII
    Z0O4TJ588O
    Posiphen is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen in Subjects With Early Alzheimer's Disease).
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(3aS,8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate
    2.1.2 InChI
    InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m0/s1
    2.1.3 InChI Key
    PBHFNBQPZCRWQP-AZUAARDMSA-N
    2.1.4 Canonical SMILES
    CC12CCN(C1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C
    2.1.5 Isomeric SMILES
    C[C@]12CCN([C@H]1N(C3=C2C=C(C=C3)OC(=O)NC4=CC=CC=C4)C)C
    2.2 Other Identifiers
    2.2.1 UNII
    Z0O4TJ588O
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. N-phenylcarbamoyl Eseroline

    2. N-phenylcarbamoyleseroline

    3. Phenserine

    2.3.2 Depositor-Supplied Synonyms

    1. (+)-phenserine

    2. R-phenserine

    3. 116839-68-0

    4. (+)-posiphen

    5. Phenserine, (+)-

    6. Buntanetap

    7. Anvs401

    8. Buntanetap [usan]

    9. (+)-phenylcarbamoyleseroline

    10. Anvs-401

    11. Z0o4tj588o

    12. (+)-o-(phenylcarbamoyl)eseroline

    13. (3ar,8as)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl Phenylcarbamate

    14. Pyrrolo(2,3-b)indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(n-phenylcarbamate), (3ar,8as)-

    15. Unii-z0o4tj588o

    16. Chembl4297417

    17. Dtxsid001110145

    18. Who 12342

    19. Db15317

    20. Hy-16009

    21. Cs-0006062

    22. [(3as,8br)-3,4,8b-trimethyl-2,3a-dihydro-1h-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate

    2.4 Create Date
    2006-10-26
    3 Chemical and Physical Properties
    Molecular Weight 337.4 g/mol
    Molecular Formula C20H23N3O2
    XLogP32.3
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count3
    Exact Mass337.17902698 g/mol
    Monoisotopic Mass337.17902698 g/mol
    Topological Polar Surface Area44.8 Ų
    Heavy Atom Count25
    Formal Charge0
    Complexity507
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Cholinesterase Inhibitors

    Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. (See all compounds classified as Cholinesterase Inhibitors.)

    Post Enquiry
    POST ENQUIRY